Grey Hair May Be a Defence Against Melanoma, University of Tokyo Study Suggests

In a laboratory in Tokyo, scientists have been watching something unusual: when certain hair cells are damaged, they do not attempt to repair themselves.

They disappear.

Far from being a minor biological detail, this cellular “giving up” may help explain a familiar sight in the mirror: hair turning grey or white over time.

Grey hair as a sign of internal defence

Research from the University of Tokyo’s Institute of Medical Science, published in Nature Cell Biology in 2025, offers a striking interpretation: in many cases, greying hair may be a visible sign of a protective system against skin cancer.

The study centres on pigment stem cells, known as McSCs, which reside in hair follicles and generate melanocytes, the cells responsible for hair colour. When these cells sustain substantial DNA damage, they may take an irreversible route rather than continue dividing and risk becoming a tumour.

Scientists suggest that, by losing pigment and turning grey, hair may reveal a silent process of cellular “self-sacrifice” against cancer.

This process has been called “seno-differentiation”: the damaged cell is driven into terminal differentiation and then disappears. The cost is a loss of colour. The likely benefit is a lower risk of melanoma, one of the most aggressive forms of skin cancer.

How this protective mechanism works

The role of pigment stem cells

Within each hair follicle, McSCs exist in a tightly regulated setting known as a “niche”. There, chemical signals determine whether they remain inactive, multiply or become pigment-producing cells.

If their DNA suffers serious damage, such as double-strand breaks, a pathway well known in oncology comes into play: the p53–p21 axis. This system is already recognised as a kind of emergency brake against tumours in several body tissues.

In hair, researchers found in mice that under stresses such as X-ray exposure, damaged McSCs stop renewing themselves and are directed towards seno-differentiation. Over successive hair-growth cycles, the visible result is the appearance of grey or white hairs.

When the p53–p21 pathway is activated, the cell accepts “dying as pigment” rather than “living as a possible cancer”.

The experiments used real-time cell-tracking techniques and gene-expression analysis, enabling the researchers to follow the fate of these cells across hair-growth cycles under different stressful conditions.

When the system fails: carcinogens enter the picture

The research also revealed the other side of the equation: in some situations, this biological brake can be undermined. When cells are exposed to carcinogens, such as the chemical DMBA or UVB radiation, the protective pathway may be blocked despite clearly damaged DNA.

In these circumstances, instead of sacrificing themselves, McSCs retain their ability to multiply. They carry genetic damage yet remain alive within the follicle. This creates favourable conditions for pre-melanoma clones to develop.

A key player in this diversion is KITL, the KIT ligand, a protein produced both by the skin and by the follicle structure itself. It activates the KIT signalling pathway, which in turn weakens the p53–p21 axis. Put simply, the signal saying “stop, step aside” is drowned out by one saying “keep growing”.

• With high KITL: more damaged cells survive, with a greater risk of melanocytic lesions.
• With low KITL: more greying occurs, but the likelihood of melanoma formation falls.

Genetically modified mice confirmed this pattern: animals with excess KITL retained damaged McSCs after carcinogen exposure and developed more changes consistent with early tumour formation. Those that did not produce KITL in the follicle region became greyer, but had a lower incidence of tumour lesions.

Ageing: when the cell environment also becomes unwell

The Japanese study did not stop at individual cells. The researchers also examined the “neighbourhood” in which they live - the niche - and how it changes with age.

As ageing progresses, the niche becomes less effective. In older mice, the researchers found reduced p53 pathway activity in skin stem cells that coexist with McSCs. Alongside this reduction, some molecules involved in the DNA-damage response were also present in lower amounts.

Interestingly, production of factors such as KITL may decrease, but this does not automatically mean greater protection. A combination of faulty signals, chronic inflammation and disruption to other metabolic pathways, such as the arachidonic acid pathway, changes how cells interpret stress.

Condition	Typical fate of McSCs	Estimated risk
Damaged DNA + active p53	Seno-differentiation and greying	Lower risk of melanoma
Damaged DNA + carcinogen + high KIT	Survival and proliferation	Higher tumour risk
Ageing of the niche	Irregular responses	Reduced surveillance, variable risk

In this setting, grey hair is no longer such a direct reflection of this cellular “clean-up” mechanism. In older people, whether greying appears may reflect a complex mixture of genetics, environment, carcinogen exposure and the niche’s capacity to respond.

Grey hair and cancer: two outcomes tied to the same choice

The study authors describe this dynamic as the “antagonistic fates” of pigment stem cells. Under stress, the same cell may take one of two paths: contribute to the visible ageing of hair or give rise to a focus of skin cancer.

On one side is the hair that loses its colour because the cell has left the stage. On the other is hair that remains pigmented while concealing, nearby, a persistent group of mutated cells.

The research suggests that the body is constantly negotiating between ageing a little more and facing less cancer risk, or preserving a youthful appearance at the cost of looser cellular surveillance.

This perspective may help explain why some people develop melanoma without a notable history of intense sun exposure, while others turn grey very early and never develop skin cancer. The way this “decision-making system” is programmed in each body makes a difference.

What this means in practice for readers

Having grey hair does not suddenly become a walking medical test. However, the study reinforces several useful points:

• greying may partly reflect the body’s effective ability to remove problematic cells;
• chronic exposure to carcinogens, such as intense sunlight without protection or certain chemical substances, tends to undermine these natural brakes;
• healthy ageing is not only about “avoiding wrinkles”, but also about protecting the quality of the signals that guide cells.

For people who already have plenty of white hairs, it is worth dropping the automatic association between greying and a “weak body”. In many instances, such hair may tell the story of a defence system that has worked hard over the years.

Conversely, someone whose hair is still dark at 60 is not automatically at an advantage. If the signalling that should push damaged cells out of play has been compromised, this preserved appearance may come with a less watchful cellular environment.

Concepts worth understanding

Several terms from the study help to organise these ideas:

• Pigment stem cell (McSC): a “parent” cell that gives rise to melanocytes, which produce melanin and hair colour;
• p53–p21 pathway: a group of genes that act as a brake on cells with damaged DNA;
• Seno-differentiation: a process in which a damaged cell is pushed into a final state, with no opportunity to divide again;
• KIT/KITL: a signalling system that encourages survival and growth, and which can interfere with the p53 brake in certain contexts;
• Niche: the microenvironment where stem cells live and receive signals that determine what they should do.

Imagine a miniature hair salon inside every follicle. McSCs would be the colour specialists. The p53 system would be the safety manager, ready to remove any worker who turns up drunk on mutations. KITL would be the insistent client asking for “just one more dye job”, encouraging the team to carry on even when exhausted. Over time, if management fails and the intrusive client becomes more powerful than everyone else, the risk of disaster rises.

This metaphor illustrates why researchers are already considering therapies that strengthen this molecular “management”. Rather than only attacking established tumours, future treatments could stimulate seno-differentiation in suspicious cells, lowering melanoma risk at very early stages, before any mark appears on the skin.